| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Volagidemab (anti-GCGR)
CAS:1233956-13-2
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K13819
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Volagidemab
CAS:1233956-13-2
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Volagidemab
CAS:1233956-13-2
Purity:95% Package:1mg;1g;100g
|
| Company Name: |
Hubei Weideli Chemical Reagent Co., Ltd.
|
| Tel: |
15871722230 |
| Email: |
15871722230@163.com |
| Products Intro: |
Product Name:Volagidemab
CAS:1233956-13-2
Purity:＞98% 可根据需求包装 Package:1G/25G/100G/250G/1000G/25KG
|
|
| | Volagidemab Basic information |
| Product Name: | Volagidemab | | Synonyms: | Volagidemab;Research Grade Volagidemab (DHE51801);Research Grade Volagidemab;Volagidemab (anti-GCGR) | | CAS: | 1233956-13-2 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Volagidemab Structure]() |
| | Volagidemab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Volagidemab Usage And Synthesis |
| Uses | Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D)[1][2]. | | in vivo | Volagidemab (5 mg/kg, s.c.) suppresses type 1 diabetes phenotype in Alloxan-induced diabetic mice[2].
| Animal Model: | Alloxan-induced diabetic mice [2] | | Dosage: | 5 mg/kg | | Administration: | Subcutaneous injection (s.c.) | | Result: | Reduced phosphorylated CREB protein and PEPCK protein expression to nondiabetic levels. |
| | References | [1] Pettus J, et al. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med. 2022 Oct;28(10):2092-2099. DOI:10.1038/s41591-022-02011-x
[2] Wang MY, et al. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2503-8. DOI:10.1073/pnas.1424934112 |
| | Volagidemab Preparation Products And Raw materials |
|